Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Merestinib and LY2874455 in Relapsed or Refractory Acute Myeloid Leukemia
NCT03125239Phase 1Completed
- Start
- Aug 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of merestinib and LY2874455 in acute myeloid leukemia (AML). Primary endpoint: Maximum Tolerated Dose at 35 days. Started Aug 2017; status: completed.
02
Drugs
merestinibLY2874455
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03125239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125239.